This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Compared to Estimates, Johnson & Johnson (JNJ) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2% and 0.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Q4 Earnings: 3 Consumer Staples Titans on Deck
by Derek Lewis
Among the bunch of companies expected to report in the coming days include a few consumer staples titans such as Procter & Gamble, Johnson & Johnson, and Kimberly-Clark.
Big Trading Day Ends with Q4 Earnings Beats: NFLX, UAL, COF
by Mark Vickery
Indexes have rocketed up from 2025 lows hit a week to a week and a half ago.
Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study
by Zacks Equity Research
NBTX stock rises following initiation of dosing in a mid-stage NSCLC study evaluating a potential first-in-class radioenhancer, JNJ-1900.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Earnings?
by Zacks Equity Research
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. It remains to be seen if MedTech sales improved.
Markets Await for Q4 Earnings
by Zacks Equity Research
Markets Await for Q4 Earnings
Markets Closed for MLK Day; Trump II Inauguration Today
by Mark Vickery
President-elect Trump becomes the second U.S. president after Grover Cleveland in 1892 to be elected to two non-consecutive terms.
A New U.S. Presidency Begins: Global Week Ahead
by John Blank
Trump's inauguration on Jan. 20th as the 47th U.S. president will likely bring with it a Day One-barrage of executive orders on anything from taxes to tariffs.
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
by Kinjel Shah
J&J offers to buy ITCI for $14.6 billion. LLY announces disappointing preliminary sales numbers for the fourth quarter.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $147.77, denoting a +1.93% change from the preceding trading day.
Insights Into Johnson & Johnson (JNJ) Q4: Wall Street Projections for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Johnson & Johnson (JNJ), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug
by Zacks Equity Research
JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer patients.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for HDV
The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular
by Zacks Equity Research
J&J, Eli Lilly, GSK and Intra-Cellular are included in this Analyst Blog.
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference
by Kinjel Shah
J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.
What Lies Ahead for Dow ETF in Q4 Earnings?
by Sweta Killa
The Dow Jones is performing better amid the rise in Treasury yields and the tech sell-off. The trend might continue as we head into the fourth-quarter earnings season.
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer
by Zacks Equity Research
JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end.
FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab
by Zacks Equity Research
JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients.
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal
by Kinjel Shah
FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.
HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up
by Zacks Equity Research
Halozyme reiterates full-year 2024 financial guidance and raises its financial outlook for 2025. Shares rise.